Company: LRHC
Filing Date: 2025-07-17
Form Type: 424B3
Source: 0001213900-25-065175
Chunk: 38

Company: La Rosa Holdings Corp.
Filing Date: 2025-07-17
Form: 424B3
Chunk 38
---
atory agreed, subject to certain customary exceptions, not to sell, offer to sell, contract or agree to sell, pledge or otherwise dispose of, directly or indirectly, shares common stock held by them for a specified period after the Closing Date.

The foregoing descriptions of the SPA, Notes,
Incremental Warrants, the Security Agreement, the Lock-Up Agreements, the Voting Agreement, the Subsidiary Guaranty, and the Registration
Rights Agreement is qualified in its entirety by reference to the full text of such agreements, copies of which are filed as exhibits
to the registration statement of which this Prospectus forms a part.

Stockholder Approval

The Company is currently listed on the Nasdaq
Capital Market and is subject to the listing rules of The Nasdaq Stock Market LLC. The issuance of the Shares implicate certain of the
Nasdaq listing standards requiring prior stockholder approval in order to maintain our listing on Nasdaq. On February 4, 2025, Joseph
La Rosa, the Company’s Chief Executive Officer, President and Chairman, as the majority stockholder of the Company, in accordance
with Nasdaq Listing Rules 5635(b) and 5635(d), approved (i) the entry into the SPA and the transactions contemplated thereunder, including
the issuance of the Notes and Incremental Warrants, (ii) the issuance of shares of common stock issuable upon the full conversion of
the Notes. The Company has filed a preliminary and definitive information statements on Schedule 14C with the SEC and mailed such definitive
information statement to the stockholders of records as of the close of business on February 4, 2025 notifying the stockholders of such
written consent in lieu of having a stockholders’ meeting on or around March 7, 2025.

Pursuant to the terms of the Exchange Agreement,
conversion of the Series B Preferred Stock into shares of common stock of the Company in excess of 19.99% of the Company’s outstanding
shares of common stock is conditional upon obtaining the approval of the Company’s stockholders in accordance with the rules and
regulations of the Nasdaq Capital Market. The Company agreed to convene a meeting of stockholders to obtain such approval within 120
days after the date of the Exchange Agreement.

<div align='center'>20

SELLING STOCKHOLDER</div>

This Prospectus relates to the possible resale
from time to time by the Selling Stockholder named in the table below of any or all of the common stock that